Systemic LAmB treatment for IPA reported a few adverse events, including infusion-associated toxicity (primarily fever, chills, and hypoxemia), renal toxicity, anemia, and hypokalemia [8]. Here, GRAMD1B is linked to Ito hypomelanosis.